Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30671919 | 1.00 | CHRM1 (0.53) | CHRM1CYP11B1CYP11B2CD38TYK2 | |
| SCHEMBL30671875 | 0.89 | CHRM1 (0.65) | CHRM1CYP11B1CYP11B2CD38 | |
| SCHEMBL26966572 | 0.89 | CHRM1 (0.65) | CHRM1CYP11B1CYP11B2CD38 | |
| SCHEMBL26966605 | 0.85 | CHRM1 (0.55) | CHRM1CYP11B1CYP11B2CSF1R | |
| SCHEMBL26966623 | 0.85 | CHRM1 (0.49) | CHRM1TYK2 | |
| SCHEMBL30671924 | 0.85 | CHRM1 (0.49) | CHRM1TYK2 | |
| SCHEMBL30671916 | 0.85 | CHRM1 (0.55) | CHRM1CYP11B1CYP11B2CSF1R | |
| SCHEMBL30671892 | 0.83 | CHRM1 (0.60) | CHRM1 | |
| SCHEMBL26966586 | 0.83 | CHRM1 (0.60) | CHRM1 | |
| SCHEMBL30671900 | 0.82 | CHRM1 (0.58) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2023-12-26 | — | — | US | claimed |
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2023-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851406-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CYP11B1 2257/4885CYP11B2 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.